Drug Trial Radar · NCT07523997
Imaging of Endometriosis With Total-body PET-CT (PET-Endo)
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Apr 8, 2026
Primary completion
Apr 1, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- University of EdinburghAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Life Molecular Imaging Ltd.
- First posted
- Apr 13, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Endometriosis is a disease that affects 1 in 10 women and is associated with debilitating pain and infertility. Endometriosis is where cells similar to those lining the womb (the 'endometrium') grow elsewhere in the body, forming 'lesions'. Most commonly the lesions grow on the lining of the pelvic cavity, called 'peritoneal' endometriosis. Lesions can also grow on the ovary, this is called 'ovarian' endometriosis, or form nodules, called 'deep' endometriosis. At present the only way to confidently identify endometriosis is through surgery, this exposes patient to the risks of surgery and contributes to the diagnostic delay associated with endometriosis. PET/CT is a specialist scan that is commonly used to identify cancers which cannot be seen on other types of scans. PET/CT uses a 'tracer', a substance given into a vein which then temporarily accumulates in areas of disease. This project will determine if a new specialist scan, total body PET/CT, and novel tracers that were developed for other conditions can be used to identify some of the key pathways in endometriosis: bleeding and scarring. Being able to identify these processes in endometriosis lesions and being able to track how they change over time would improve our understanding of endometriosis. The investigators also want to know if these pathways are different between superficial, deep and ovarian endometriosis, and what the impact is of the hormones related to the menstrual cycle. In this study up to 30 people who have suspected endometriosis and are already due to undergo diagnostic surgery will be asked to undergo two total-body PET/CT scans in Edinburgh, one at one visit and one another visit. Participants will also have a PET/MRI scan at visit. Participants will have a different tracer at each visit. The investigators will then compare the scan findings with their subsequent surgical findings.
Conditions
- Endometriosis
Interventions
PET/CTDiagnostic test
Hybrid positron emission tomography and computed tomography will be performed after intravenous administration of the 68Ga-FAPI or the 18F-GP1 radiotracer and images centred on the pelvis. Attenuation-correction CT will be performed before acquisition of PET data
PET/MRIDiagnostic test
Hybrid PET/MRI will be performed on a 3T scanner with T1 mapping immediately after the PET/CT with images acquired centred on the pelvis after injection of buscopan
Buscopan 20 MG/ML Injectable SolutionDrug
IV injection prior to PET/MRI
Primary outcomes
What the sponsor says the trial is designed to measure.
- In vivo uptake of 18F-GP1 and 68Ga-FAPI in endometriosisTime frame: within 3 months post surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh
Edinburgh, City Of Edinburgh, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.